Temat: "Antineoplastic Combined Chemotherapy Protocols" - OpacWWW

Skocz do pozycji: 41.

Tytuł:: Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
Autorzy:: Huan L; Department of Hepatopancreatobiliary Surgery, Chongqing Fifth People's Hospital, Chongqing, Chongqing, China.
Yu F; Department of Hepatopancreatobiliary Surgery, Chongqing Fifth People's Hospital, Chongqing, Chongqing, China.
Cao D; Department of Hepatopancreatobiliary Surgery, Chongqing Fifth People's Hospital, Chongqing, Chongqing, China.
Zhou H; Department of Hepatopancreatobiliary Surgery, Chongqing Fifth People's Hospital, Chongqing, Chongqing, China.
Qin M; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China.
Cao Y; Department of Hepatopancreatobiliary Surgery, Chongqing Fifth People's Hospital, Chongqing, Chongqing, China.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Mar 07; Vol. 19 (3), pp. e0295983. Date of Electronic Publication: 2024 Mar 07 (Print Publication: 2024).
Typ publikacji:: Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:: Neoadjuvant Therapy*/methods
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/surgery
Humans ; Gemcitabine ; Capecitabine/therapeutic use ; Cisplatin/therapeutic use ; Epirubicin/therapeutic use ; Network Meta-Analysis ; Bayes Theorem ; Randomized Controlled Trials as Topic ; Deoxycytidine/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 42.

Tytuł:: LABS score- a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: a single-center retrospective study.
Autorzy:: Wonglhow J; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Sunpaweravong P; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Sathitruangsak C; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Dechaphunkul A; Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Mar 01; Vol. 24 (1), pp. 281. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Hepatocellular*
Liver Neoplasms*/pathology
Humans ; Prognosis ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Fluorouracil ; Leucovorin ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 43.

Tytuł:: Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.
Autorzy:: Chao L; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Liu J; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Chen Y; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Fan Y; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Guo S; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Zhang S; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2024 Mar; Vol. 15 (8), pp. 622-629. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:: Journal Article
MeSH Terms:: Esophageal Squamous Cell Carcinoma*/drug therapy
Esophageal Squamous Cell Carcinoma*/surgery
Esophageal Neoplasms*/drug therapy
Esophageal Neoplasms*/surgery
Esophageal Neoplasms*/pathology
Antibodies, Monoclonal, Humanized*
Humans ; Carboplatin/therapeutic use ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Retrospective Studies ; Induction Chemotherapy ; Neoadjuvant Therapy ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Albumins/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 44.

Tytuł:: Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
Autorzy:: Yonemori K; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. .
Fujiwara K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Hasegawa K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Yunokawa M; Department of Gynecology, Cancer Institute Hospital of JFCR, Tokyo, Japan.
Ushijima K; Department of Obstetrics and Gynecology, Kurume University Hospital, Fukuoka, Japan.
Suzuki S; Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
Shikama A; Department of Obstetrics and Gynecology, University of Tsukuba Hospital, Ibaraki, Japan.
Minobe S; Division of Gynecologic Oncology, Hokkaido Cancer Center, Hokkaido, Japan.
Usami T; Department of Obstetrics and Gynecology, Ehime University Hospital, Ehime, Japan.
Kim JW; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Kim BG; Division of Gynecologic Cancer, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Wang PH; Institute of Clinical Medicine, National Yang Ming Chiao Tung University; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital; Female Cancer Foundation, Taipei, Taiwan; China Medical University Hospital, Taichung, Taiwan.
Chang TC; Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University Medical College, Kueishan, Taoyuan City, Taiwan.
Yamamoto K; Oncology Science Unit, MSD K.K., Tokyo, Japan.
Han S; Biostatistics & Research Decision Sciences, MSD K.K., Tokyo, Japan.
McKenzie J; Eisai Inc., Nutley, NJ, USA.
Orlowski RJ; Global Clinical Development, Merck & Co., Inc., Rahway, NJ, USA.
Miura T; Clinical Oncology, Eisai Co., Ltd., Tokyo, Japan.
Makker V; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
Man Kim Y; Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan, Seoul, Korea.; Pokaż więcej
Źródło:: Journal of gynecologic oncology [J Gynecol Oncol] 2024 Mar; Vol. 35 (2), pp. e40. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:: Randomized Controlled Trial; Journal Article
MeSH Terms:: Endometrial Neoplasms*/drug therapy
Endometrial Neoplasms*/etiology
Physicians*
Phenylurea Compounds*
Quinolines*
Antibodies, Monoclonal, Humanized*
Humans ; Female ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/etiology ; Asia, Eastern/epidemiology ; Antineoplastic Combined Chemotherapy Protocols

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 45.

Tytuł:: Adjuvant carboplatin and paclitaxel with "sandwich" method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution.
Autorzy:: Chinnadurai A; Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Breadner D; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.; Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. .
Baloush Z; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.
Lohmann AE; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.
Black M; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.
D'Souza D; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.; Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Welch S; London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada.; Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.; Pokaż więcej
Źródło:: Journal of gynecologic oncology [J Gynecol Oncol] 2024 Mar; Vol. 35 (2), pp. e16. Date of Electronic Publication: 2023 Oct 16.
Typ publikacji:: Journal Article
MeSH Terms:: Paclitaxel*
Endometrial Neoplasms*/drug therapy
Endometrial Neoplasms*/radiotherapy
Adult ; Humans ; Female ; Middle Aged ; Aged ; Aged, 80 and over ; Carboplatin ; Follow-Up Studies ; Cohort Studies ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Staging ; Chemotherapy, Adjuvant/methods ; Radiotherapy, Adjuvant

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 46.

Tytuł:: Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect.
Autorzy:: Hu Z; Bristol Myers Squibb, Princeton, New Jersey, USA.
Liu S; Bristol Myers Squibb, Princeton, New Jersey, USA.
Zhao Y; Bristol Myers Squibb, Princeton, New Jersey, USA.
Du S; Bristol Myers Squibb, Princeton, New Jersey, USA.
Hamuro L; Bristol Myers Squibb, Princeton, New Jersey, USA.
Shen J; Bristol Myers Squibb, Princeton, New Jersey, USA.
Roy A; Bristol Myers Squibb, Princeton, New Jersey, USA.
Zhu L; Bristol Myers Squibb, Princeton, New Jersey, USA.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 476-493. Date of Electronic Publication: 2024 Jan 08.
Typ publikacji:: Journal Article
MeSH Terms:: Melanoma*/drug therapy
Lymphoma*
Adult ; Humans ; Child ; Nivolumab ; Ipilimumab ; Antibodies, Monoclonal/pharmacokinetics ; Body Size ; Antineoplastic Combined Chemotherapy Protocols

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 47.

Tytuł:: Real-life experiences and barriers to adjuvant chemotherapy in Saudi patients with advanced stage II and stage III colon cancer.
Autorzy:: Alyabsi MS; Population Health Research Section, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Alqarni AH; Population Health Research Section, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Princess Noura Bint Abdul Rahman University, Health, and Rehabilitation Sciences College, Riyadh, Saudi Arabia.
Almutairi AF; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Alselaim NA; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Algarni MA; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Department of Oncology, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia.
Alshammari KM; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; Department of Oncology, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia.; Pokaż więcej
Źródło:: Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2024 Mar 01; Vol. 30 (2), pp. 114-122. Date of Electronic Publication: 2023 Nov 07.
Typ publikacji:: Journal Article
MeSH Terms:: Fluorouracil*
Colonic Neoplasms*/drug therapy
Colonic Neoplasms*/epidemiology
Colonic Neoplasms*/pathology
Male ; Female ; Humans ; Oxaliplatin/therapeutic use ; Saudi Arabia/epidemiology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 48.

Tytuł:: Breast lump as the initial presentation of metastatic uterine leiomyosarcoma: a case report and comprehensive literature review.
Autorzy:: Ibisevic N
Tomic K
Humackic A
Guzin Z
Lukic B
Vranic S; Semir Vranic, College of Medicine, QU Health, Qatar University, PO Box 2713, Doha, Qatar, .; Pokaż więcej
Źródło:: Croatian medical journal [Croat Med J] 2024 Feb 29; Vol. 65 (1), pp. 51-58.
Typ publikacji:: Review; Case Reports
MeSH Terms:: Leiomyosarcoma*/diagnostic imaging
Leiomyoma*
Lung Neoplasms*
Female ; Humans ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols ; Liver

Recenzja

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 49.

Tytuł:: Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
Autorzy:: Smabers LP; Department of Medical Oncology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
Wensink E; Department of Medical Oncology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
Verissimo CS; HUB Organoids B.V, Utrecht, The Netherlands.
Koedoot E; HUB Organoids B.V, Utrecht, The Netherlands.
Pitsa KC; HUB Organoids B.V, Utrecht, The Netherlands.
Huismans MA; Molecular Cancer Research, Center for Molecular Medicine, UMCU, Utrecht, The Netherlands.
Higuera Barón C; HUB Organoids B.V, Utrecht, The Netherlands.
Doorn M; HUB Organoids B.V, Utrecht, The Netherlands.
Valkenburg-van Iersel LB; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands.
Cirkel GA; Department of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands.
Brousali A; Utrecht Platform for Organoid Technology (UPORT), UMCU, Utrecht, The Netherlands.
Overmeer R; HUB Organoids B.V, Utrecht, The Netherlands.
Koopman M; Department of Medical Oncology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
Braat MN; Department of Radiology, UMCU, Utrecht, The Netherlands.
Penning de Vries B; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, UMCU, Utrecht, The Netherlands.
Elias SG; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, UMCU, Utrecht, The Netherlands.
Vries RG; HUB Organoids B.V, Utrecht, The Netherlands.
Kranenburg O; Utrecht Platform for Organoid Technology (UPORT), UMCU, Utrecht, The Netherlands.; Laboratory of Translational Oncology, Division of Imaging and Cancer, UMCU, Utrecht, The Netherlands.
Boj SF; HUB Organoids B.V, Utrecht, The Netherlands. .
Roodhart JM; Department of Medical Oncology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands. .; Pokaż więcej
Źródło:: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Feb 27; Vol. 43 (1), pp. 61. Date of Electronic Publication: 2024 Feb 27.
Typ publikacji:: Journal Article
MeSH Terms:: Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colonic Neoplasms*/drug therapy
Humans ; Irinotecan/pharmacology ; Irinotecan/therapeutic use ; Oxaliplatin/pharmacology ; Oxaliplatin/therapeutic use ; Acetylcysteine/therapeutic use ; Precision Medicine ; Fluorouracil/pharmacology ; Fluorouracil/therapeutic use ; Organoids ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 50.

Tytuł:: Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study.
Autorzy:: Gueiderikh A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Université Paris Saclay, 91471, Orsay, France.
Tarabay A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Abdelouahab M; Département de statistiques, Gustave Roussy, 94800, Villejuif, France.
Smolenschi C; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Gustave Roussy, DITEP, 94800, Villejuif, France.
Tanguy ML; Département de statistiques, Gustave Roussy, 94800, Villejuif, France.
Valery M; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Malka D; Département d'oncologie médicale, Institut Mutualiste Montsouris, 75014, Paris, France.
Pudlarz T; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Fuerea A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Boige V; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Hollebecque A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Gustave Roussy, DITEP, 94800, Villejuif, France.
Ducreux M; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Université Paris Saclay, 91471, Orsay, France.
Boilève A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France. .; Université Paris Saclay, 91471, Orsay, France. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 26; Vol. 24 (1), pp. 272. Date of Electronic Publication: 2024 Feb 26.
Typ publikacji:: Journal Article
MeSH Terms:: Pancreatic Neoplasms*/pathology
Adenocarcinoma*/pathology
Humans ; Gemcitabine ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Retrospective Studies ; Erlotinib Hydrochloride/therapeutic use ; Deoxycytidine ; Fluorouracil ; Leucovorin/therapeutic use ; Paclitaxel ; Albumins

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 51.

Tytuł:: Primary thyroid lymphoma: a case series.
Autorzy:: Sakhri S; Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Zemni I; Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. .; LMBA (LR03ES03), Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia. .
Ayadi MA; Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.; LMBA (LR03ES03), Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia.
Kamoun S; Department of Pathology, Salah Azaïz Institute, Faculty of Medicine, University Tunis El Manar, Tunis, Tunisia.
Chargui R; Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Ben Dhiab T; Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.; Pokaż więcej
Źródło:: Journal of medical case reports [J Med Case Rep] 2024 Feb 24; Vol. 18 (1), pp. 108. Date of Electronic Publication: 2024 Feb 24.
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Thyroid Neoplasms*/pathology
Lymphoma, Non-Hodgkin*
Lymphoma, Large B-Cell, Diffuse*/diagnosis
Lymphoma, Large B-Cell, Diffuse*/therapy
Lymphoma, Large B-Cell, Diffuse*/pathology
Male ; Humans ; Female ; Aged ; Rare Diseases ; Doxorubicin/therapeutic use ; Prednisone/therapeutic use ; Vincristine/therapeutic use ; Rituximab ; Cyclophosphamide/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 52.

Tytuł:: Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy.
Autorzy:: Arqueros C; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.; Department of Medicine, Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Gallardo A; Department of Pathology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.; Department of Morphological Sciences, Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Institut de Recerca Sant Pau-CERCA Center, 08041 Barcelona, Spain.
Vidal S; Inflammatory Diseases, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Institut de Recerca Sant Pau-CERCA Center, 08041 Barcelona, Spain.
Osuna-Gómez R; Inflammatory Diseases, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Institut de Recerca Sant Pau-CERCA Center, 08041 Barcelona, Spain.
Tibau A; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Lidia Bell O; Translational Medical Oncology Laboratory, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Institut de Recerca Sant Pau-CERCA Center, 08041 Barcelona, Spain.
Ramón Y Cajal T; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Lerma E; Department of Pathology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.; Department of Morphological Sciences, Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Institut de Recerca Sant Pau-CERCA Center, 08041 Barcelona, Spain.
Lobato-Delgado B; Unitat de Genòmica de Malalties Complexes, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau-CERCA Center, 08041 Barcelona, Spain.
Salazar J; Translational Medical Oncology Laboratory, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Institut de Recerca Sant Pau-CERCA Center, 08041 Barcelona, Spain.
Barnadas A; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.; Department of Medicine, Faculty of Medicine, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Translational Medical Oncology Laboratory, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Institut de Recerca Sant Pau-CERCA Center, 08041 Barcelona, Spain.; Centro de Investigación Biomedica en Red Cancer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Feb 23; Vol. 25 (5). Date of Electronic Publication: 2024 Feb 23.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/pathology
Humans ; Female ; Neoadjuvant Therapy/adverse effects ; Clinical Relevance ; Retrospective Studies ; Biomarkers, Tumor/analysis ; Lymphocytes, Tumor-Infiltrating ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 53.

Tytuł:: [Effect of venetoclax plus chemotherapy on treatment-naive acute myeloid leukemia patients with moderate to poor cytogenetic profiles and the combination's influence on the expression of proteins of the anti-apoptoic family].
Źródło:: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Feb 23; Vol. 46 (2), pp. 161-167.
Typ publikacji:: English Abstract; Journal Article; Observational Study; Randomized Controlled Trial
MeSH Terms:: Bridged Bicyclo Compounds, Heterocyclic*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Sulfonamides*
Adult ; Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cytarabine/therapeutic use ; Cytogenetic Analysis ; Myeloid Cell Leukemia Sequence 1 Protein/therapeutic use ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 54.

Tytuł:: Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).
Autorzy:: Lim SH; Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Seoul, South Korea.; Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, South Korea.
Lee KW; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. .
Kim JJ; Department of Internal Medicine, School of Medicine, Pusan National University Yangsan Hospital, Pusan National University, Yangsan, Republic of Korea.
Im HS; Department of Hematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, South Korea.
Kim IH; Division of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Han HS; Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea.
Koo DH; Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Cho JH; Division of Oncology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Maeng CH; Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, South Korea.
Lee MY; Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, South Korea.
Lee HJ; Division of Hemato-Oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea.
Kim JH; Department of Internal Medicine, Anam Hospital, Korea University College of Medicine, Seoul, South Korea.
Park SG; Department of Hemato-Oncology, Chosun University Hospital, Gwangju, South Korea.
Jung JY; Division of Hemato-Oncology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea.
Shin SH; Department of Hemato/Oncology, Internal Medicine, Kosin University Gospel Hospital, Busan, South Korea.
Kim KH; Division of Oncology, Department of Internal Medicine, Inje University College of Medicine, Busan Paik Hospital, Busan, South Korea.
Kim H; Department of Hematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, South Korea.
Oh SY; Department of Internal Medicine, School of Medicine, Pusan National University Yangsan Hospital, Pusan National University, Yangsan, Republic of Korea.
Kang M; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Jung M; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.
Rha SY; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 23; Vol. 24 (1), pp. 252. Date of Electronic Publication: 2024 Feb 23.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Stomach Neoplasms*/pathology
Peritoneal Neoplasms*/drug therapy
Niacinamide/*analogs & derivatives
Humans ; Irinotecan ; Immune Checkpoint Inhibitors/adverse effects ; B7-H1 Antigen ; Camptothecin ; Retrospective Studies ; Fluorouracil ; Leucovorin ; Republic of Korea/epidemiology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 55.

Tytuł:: Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
Autorzy:: de Moraes FCA; Federal University of Pará, 66073-005, Belém, Pará, Brazil. .
Pasqualotto E; Federal University of Santa Catarina, 88040-900, Florianópolis, Santa Catarina, Brazil.
Chavez MP; Federal University of Santa Catarina, 88040-900, Florianópolis, Santa Catarina, Brazil.
Ferreira ROM; Federal University of Santa Catarina, 88040-900, Florianópolis, Santa Catarina, Brazil.
De Castria TB; Moffitt Cancer Center, 12902 USF Magnolia Drive, 33612, Tampa, FL, USA.; Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd., 33612, Tampa, FL, USA.
Burbano RMR; Ophir Loyola Hospital, 66063-240, Belém, Pará, Brazil.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 21; Vol. 24 (1), pp. 240. Date of Electronic Publication: 2024 Feb 21.
Typ publikacji:: Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:: Stomach Neoplasms*/pathology
Adenocarcinoma*/pathology
Esophageal Neoplasms*
Humans ; Randomized Controlled Trials as Topic ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Esophagogastric Junction/pathology ; Claudins
SCR Disease Name:: Adenocarcinoma Of Esophagus

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 56.

Tytuł:: Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.
Autorzy:: Lang Y; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Lin Y; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Deng M; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Liu X; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 21; Vol. 24 (1), pp. 236. Date of Electronic Publication: 2024 Feb 21.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Antibodies, Monoclonal, Humanized*
Humans ; United States ; Cost-Benefit Analysis ; Antineoplastic Combined Chemotherapy Protocols ; Quality-Adjusted Life Years

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 57.

Tytuł:: Liver Transplantation for Unresectable Colorectal Liver Metastasis: Perspective and Review of Current Literature.
Autorzy:: Robinson TJ; Department of Surgery, University of Virginia, 1215 Lee Street, Charlottesville, VA 22908, USA.
Cummins K; Department of Surgery, University of Virginia, 1215 Lee Street, Charlottesville, VA 22908, USA.
Tsung A; Department of Surgery, University of Virginia, 1215 Lee Street, Charlottesville, VA 22908, USA.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Feb 16; Vol. 31 (2), pp. 1079-1090. Date of Electronic Publication: 2024 Feb 16.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Liver Transplantation*
Colorectal Neoplasms*/pathology
Liver Neoplasms*/surgery
Liver Neoplasms*/drug therapy
Humans ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Hepatectomy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 58.

Tytuł:: The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
Autorzy:: Zhang J; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yang M; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wei D; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhang D; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Chen Z; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. .
Zhu H; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 13; Vol. 24 (1), pp. 202. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/surgery
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/surgery
Antibodies, Monoclonal, Humanized*
Humans ; Cisplatin/therapeutic use ; Gemcitabine ; Retrospective Studies ; Deoxycytidine/adverse effects ; Muscles ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 59.

Tytuł:: A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.
Autorzy:: Cheng Y; Department of Oncology, Jilin Cancer Hospital, Changchun, 130000, China. .
Wu C; Department of Oncology, Jilin Cancer Hospital, Changchun, 130000, China.
Wu L; Department of Thoracic Oncology, Hunan Cancer Hospital, Changsha, 410013, China.
Zhao J; Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, 100142, China.
Zhao Y; Department of Oncology, Henan Cancer Hospital, Zhengzhou, 450003, China.
Chen L; Department of Oncology, Jilin Cancer Hospital, Changchun, 130000, China.
Xin Y; Department of Oncology, Jilin Cancer Hospital, Changchun, 130000, China.
Zhang L; Department of Oncology, Jilin Cancer Hospital, Changchun, 130000, China.
Pan P; Department of Respiratory Disease, Xiangya Hospital Central South University, Changsha, 410008, China.
Li X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Li J; Department of Oncology, Sichuan Cancer Hospital, Chengdu, 610041, China.
Dong X; Center of Oncology, Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Tang K; Clinical Research Center of Luye Pharma Group Ltd, Luye Life Sciences Group, Beijing, 100080, China.
Gao E; Clinical Research Center of Luye Pharma Group Ltd, Luye Life Sciences Group, Beijing, 100080, China.
Yu F; School of Pharmacy, Yantai University, Yantai, 264005, China.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Feb 13; Vol. 14 (1), pp. 3598. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Multicenter Study
MeSH Terms:: Anemia*/etiology
Carbolines*/adverse effects
Heterocyclic Compounds, 4 or More Rings*/adverse effects
Lung Neoplasms*/pathology
Neutropenia*/drug therapy
Small Cell Lung Carcinoma*/pathology
Thrombocytopenia*/etiology
Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; China

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 60.

Tytuł:: Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Autorzy:: Sholler GLS; Division of Pediatric Hematology/Oncology, Penn State Health Children's Hospital, 500 University Drive, MC-H085, Rm. C7621, Hershey, PA, 17033-0850, USA. .
Bergendahl G; Division of Pediatric Hematology/Oncology, Penn State Health Children's Hospital, 500 University Drive, MC-H085, Rm. C7621, Hershey, PA, 17033-0850, USA.
Lewis EC; Levine Children's Hospital, Atrium Health, Charlotte, NC, USA.
Kraveka J; Medical University of South Carolina, Charleston, SC, USA.
Ferguson W; Cardinal Glennon Children's Medical Center, St. Louis University School of Medicine, St. Louis, MO, USA.
Nagulapally AB; Division of Pediatric Hematology/Oncology, Penn State Health Children's Hospital, 500 University Drive, MC-H085, Rm. C7621, Hershey, PA, 17033-0850, USA.
Dykema K; Levine Children's Hospital, Atrium Health, Charlotte, NC, USA.
Brown VI; Division of Pediatric Hematology/Oncology, Penn State Health Children's Hospital, 500 University Drive, MC-H085, Rm. C7621, Hershey, PA, 17033-0850, USA.
Isakoff MS; Connecticut Children's Medical Center, Hartford, CT, USA.
Junewick J; Helen DeVos Children's Hospital, Spectrum Health, Grand Rapids, MI, USA.
Mitchell D; Helen DeVos Children's Hospital, Spectrum Health, Grand Rapids, MI, USA.
Rawwas J; Children's Hospitals and Clinics of Minnesota, Minneapolis, USA.
Roberts W; Rady Children's Hospital-San Diego and UC San Diego School of Medicine, San Diego, CA, USA.
Eslin D; St. Joseph's Children's Hospital, Tampa, FL, USA.
Oesterheld J; Levine Children's Hospital, Atrium Health, Charlotte, NC, USA.
Wada RK; Kapiolani Medical Center for Women and Children, University of Hawaii, Honolulu, HI, USA.
Pastakia D; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Harrod V; Dell Children's Blood and Cancer Center, Ascension Dell Children's, Austin, TX, USA.
Ginn K; Children's Mercy, Kansas City, MO, USA.
Saab R; Stanford Medicine Children's Health, Palo Alto, CA, USA.
Bielamowicz K; Arkansas Children's Hospital, Little Rock, AR, USA.
Glover J; Randall Children's Hospital, Portland, OR, USA.
Chang E; St. Luke's Cancer Institute, Boise, ID, USA.
Hanna GK; Orlando Health Cancer Institute, Orlando, FL, USA.
Enriquez D; Translational Genomics Research Institute, Phoenix, AZ, USA.
Izatt T; Translational Genomics Research Institute, Phoenix, AZ, USA.
Halperin RF; Translational Genomics Research Institute, Phoenix, AZ, USA.
Moore A; Division of Pediatric Hematology/Oncology, Penn State Health Children's Hospital, 500 University Drive, MC-H085, Rm. C7621, Hershey, PA, 17033-0850, USA.
Byron SA; Translational Genomics Research Institute, Phoenix, AZ, USA.
Hendricks WPD; Translational Genomics Research Institute, Phoenix, AZ, USA.
Trent JM; Translational Genomics Research Institute, Phoenix, AZ, USA.; Pokaż więcej
Źródło:: Genome medicine [Genome Med] 2024 Feb 12; Vol. 16 (1), pp. 28. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:: Clinical Trial; Journal Article
MeSH Terms:: Neuroblastoma*/drug therapy
Neuroblastoma*/genetics
Child ; Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/etiology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Antineoplastic Combined Chemotherapy Protocols"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji